Incidence of hyperhomocysteinemia and Mthfr C677T polymorphism among young patients with acute myocardial infarction

Journal of Medical Biochemistry

Volumn 28, Issue 1, 2009, Pages 41-45

  Beletić, Andelo ^a   Mirković, Duško ^b   Antonijević, Nebojša ^a   Dordević, Valentina ^c   Šango, Violeta ^d   Jakovljević, Branko ^d   Peruničić, Jovan ^b   Ilić, Mirka ^a   Vasiljević, Zorana ^b   Majkić Singh, Nada ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c INSTITUTE OF MOLECULAR GENETICS AND GENETIC ENGINEERING   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Hyperhomocysteinemia; MTHFR; Myocardial infarction; Young adults

Indexed keywords

HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

EID: 60249088201     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0029-9     Document Type: Article

References (26)

1. Mirković D, Majkić́-Singh N, Ignjatović S. Homocistein: hemija, metabolizam i uloga u patofiziološkim proce sima. Jugoslov Med Biohem 2003; 22: 127-40.
2. Herrmann W. Significance of hyperhomocysteinemia. Clin Lab Med 2006; 52: 367-74.
3. Kluijtmans LAJ, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101 (7): 2483-8.
4. Bathum L, Petersen I, Christiansen L, Konieczna A, Sörensen TIA, Kyvik KO. Genetic and enviromental influences on plasma homocysteine: results from a Danish twin study. Clin Chem 2007; 53 (5): 971-9.
5. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22 (4): 195-201.
6. Pinto X, Vilaseca MA. Homocysteine and the MTHFR 677 C→T allele in premature coronary artery disease. Case control and family studies. European Journal of Clinical Investigation 2001; 31 (11): 992-8.
7. Lentz SR. Mechanism of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3: 1646-54.
8. Martin-Herrero F, Martin-Moreiras J, Pabón P, Sánchez, PL, Moríñigo-Muñoz JL, Jimenez-Candil J. Homocysteine and outcome in young patients with acute coronary syndromes. Int J Cardiol 2007; 118 (2): 183-8.
9. Moat SJ. Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem 2008; 45: 345-8.
10. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Eng J Med 2006; 354 (15): 1629-32.
11. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006; 48 (5): 914-23.
12. Klerk, M, Verhoef P, Clarke R, Blom HJ, Schouten EG. MTHFR 677 C→T polymorphism and risk of coronary heart disease. JAMA 2002; 288 (16): 2023-31.
13. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677 C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331: 1053-9.
14. FácilaL, Nuñez JE, Bertomeu V, Sanchis J, Bodi V, Chorro FJ, et al. Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor? Int J Card 2005; 100: 275-9.
15. Mirković D. Homocistein kao faktor rizika za nastanak koronarne bolesti. Doktorska disertacija. Beograd, Srbija; Univerzitet u Beogradu, 2004.
16. Crossed D signorCrossed d signević V, RakiCrossed d signević Lj, Miković D, Kovać M, Radojković D, Savić A. The FV Leiden, FII G20210A and MTHFR C677T mutations in healthy and thrombophilic Yugoslav population. J Thromb Haemost 2003; (1): P0338.
17. Aslan D, Sandberg S. Simple statistic in diagnostic tests. Journal of Medical Biochemistry 2007; 26: 309-13.
18. Antonijević N, Beletić A, Jakovljević B, Mirković D, Crossed D signorCrossed d signević V, Radovanović N, et al. Conventional and novel risk factors for myocardial infarction in patients under 45 years [abstract]. Eur Heart J 2008; 29: 689.
19. Ridker PM, Libby P. Risk for atherothrombotic disease: homocysteine. In: Zipes DP, Libby P, Bonow RO, Braun - wald E. Braunwald's heart disease. Philadelphia: Elsevier Church Livingstone, 2005: 549-50.
20. Cesari M, Rossi GP, Sticchi D, Pesina AC. Is homocysteine an important risk factor for coronary heart disease? Nutr Metab Cardivasc Dis 2005; 15 (2): 140-7.
21. Undas A, Brozek J, Szckeklik M. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94: 907-15.
22. Perla-Kaján J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007; 32: 561-72.
23. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioava ila bility through oxidative stress. Circulation 2007: 115: 255-62.
24. Maron DJ, Grundy SM, Ridker PM, Pearson TA. Dyslipidemia, other risk factors and the prevention of coronary heart disease; hyperhomocysteinemia. In: Fuster V, Alexan der RW, eds. Hurst's The Heart. New York: McGraw-Hill, 2004; 1109-10.
25. Garcia-Pinilla JM, Espinosa-Caliani S, Jimenéz-Navarro M, Gómez-Doblaz JJ, Cabrera-Bueno F, Reyes-Engel A, et al. Influence of 677 C→T polymorphism of methylenetetrahydrofolate reductase on medium-term prognosis after acute coronary syndromes. Tex Heart Inst J 2007; 34: 142-7.
26. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on epidemiology and prevention, the Stroke Council and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007; 115: 2878-901.